2
项与 EX02 CAR-T(Zeno Therapeutics) 相关的临床试验An Open-label, Single-arm Clinical Study of EX02 CAR-T Therapy for Relapsed and Refractory Acute Myeloid Leukemia
This is a early Phase 1 open-label, single-arm clinical study of EX02 CAR-T therapy for relapsed and refractory acute myeloid leukemia.
Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy of cyclophosphamide and fludarabine, and an an intravenous infusion of CAR-T cells.
Each participant will proceed through the following study procedures:
* Screening
* Enrollment/Leukapheresis
* Conditioning chemotherapy
* CAR T treatment
* Post-treatment assessment
* Long-term follow-up
Early Phase I Study of Autologous T Cells Engineered to Express Anti-EX02 Chimeric Antigen Receptor (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer
This is a early Phase 1 open-label study to explore the safety and possible efficacy of EX02 CAR T cell therapy in the treatment of patients with unresectable and/or metastatic pancreatic/bile duct cancer.
Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy of cyclophosphamide and fludarabine, and an intra-tumoral injection or intraperitoneal infusion of Ex02 CAR T cells, probably followed by an intravenous infusion of EX02 CAR T cells.
Each participant will proceed through the following study procedures:
Screening
Enrollment/Leukapheresis
Conditioning chemotherapy
CAR T treatment
Post-treatment assessment
Long-term follow-up
100 项与 EX02 CAR-T(Zeno Therapeutics) 相关的临床结果
100 项与 EX02 CAR-T(Zeno Therapeutics) 相关的转化医学
100 项与 EX02 CAR-T(Zeno Therapeutics) 相关的专利(医药)
100 项与 EX02 CAR-T(Zeno Therapeutics) 相关的药物交易